ProCE Banner Activity

Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists


Download these slides to learn how oncology pharmacists can optimize care for patients receiving ADCs targeting HER2, HER3, or TROP-2, from patient education to toxicity identification and management.

Released: April 04, 2024

Expiration: April 03, 2025



Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Sandra Cuellar

Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

Clinical Oncology Pharmacist, UI Health
Clinical Associate Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.


Daiichi Sankyo, Inc.


Clinical Care Options, LLC

ProCE Banner